YK
Therapeutic Areas
Meiji Seika Pharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ME1100 (arbekacin inhalation solution) | Pulmonary infections caused by multidrug-resistant pathogens | Phase 3 |
| Cefiderocol | Infections caused by multidrug-resistant Gram-negative bacteria | Approved |
| Various oncology candidates | Multiple cancer types | Various |